Company / Operating Cash Flow
PharmaCyte Biotech, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$2.2M
FY2025
5-year range
-$4.1M / -$2.2M
FY2021-FY2025
Trend
+43.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$5M in FY2019 to -$2M in FY2016.
Based on SEC 10-K filings.
-$2M in FY2025.
Improved from -$4M to -$2M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 43.3% year-over-year.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.2M | +43.3% |
| FY2024 | -$3.8M | +7.9% |
| FY2023 | -$4.1M | -23.6% |
| FY2022 | -$3.3M | -42.4% |
| FY2021 | -$2.3M | +18.7% |
| FY2020 | -$2.9M | +43.3% |
| FY2019 | -$5.1M | -52.1% |
| FY2018 | -$3.3M | +23.2% |
| FY2017 | -$4.3M | -179.6% |
| FY2016 | -$1.6M | -298.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026